ICAAC 2012: Raltegravir Shows Long-term Safety and Efficacy for HIV/HCV and HIV/HBV Coinfection
- Details
- Category: HIV/Hepatitis Coinfection
- Published on Thursday, 20 September 2012 00:00
- Written by Liz Highleyman
The HIV integrase inhibitor raltegravir (Isentress) was well-tolerated and demonstrated continued effectiveness for 5 years in treatment-naive and 3 years in treatment-experienced HIV patients coinfected with hepatitis B or C, according to a poster presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Francisco.
ICAAC 2012: Dolutegravir HIV Regimen Superior to Atripla, Fewer Stop Due to Side Effects
- Details
- Category: HIV Treatment
- Published on Friday, 14 September 2012 00:00
- Written by Liz Highleyman
The experimental integrase inhibitor dolutegravir combined with abacavir/lamivudine (Epzicom) demonstrated statistically superior antiviral efficacy compared with the popular Atripla single-tablet regimen for first-line HIV treatment, largely because fewer people stopped using the former due to side effects, researchers reported this week at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) this week in San Francisco.
ICAAC 2012: Switching to Tenofovir in ART Regimen Suppresses Hepatitis B in HIV/HBV Coinfected
- Details
- Category: HBV Epidemiology & Mortality
- Published on Friday, 14 September 2012 00:00
- Written by Liz Highleyman
HIV/HBV coinfected people who substituted tenofovir DF (Viread) for zidovudine (AZT; Retrovir) or abacavir (Ziagen) in their antiretroviral regimen saw a reduction in hepatitis B viral load, despite HBV resistance to lamivudine (3TC; Epivir), according to a poster presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) this week in San Francisco.
ICAAC 2012: Long-acting Integrase Inhibitor S/GSK1265744 Active Against HIV Subtypes
- Details
- Category: HIV Treatment
- Published on Friday, 14 September 2012 00:00
- Written by Liz Highleyman
The experimental integrase inhibitor S/GSK1265744 exhibited potent and prolonged activity against a broad range of HIV subtypes, was active against clones with resistance to raltegravir (Isentress) and elvitegravir, and appears to have a high barrier to resistance, according to a presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this week in San Francisco.
ICAAC 2012: Are Statins Beneficial for Patients with Candida Fungal Infections?
- Details
- Category: Opportunistic Illness (OIs)
- Published on Friday, 14 September 2012 00:00
- Written by Press Release
Use of statin drugs to manage elevated cholesterol in people at risk for cardiovascular disease may also reduce short-term mortality among people with Candida fungal infections, perhaps due to their immunomodulatory properties,according to a study presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) this week in San Francisco.
More Articles...
- ICAAC 2012: Progression of Anal Neoplasia is Common among Gay Men with HIV
- ICAAC 2012: HCV Polymerase Inhibitor Sofosbuvir Appears Safe and Effective for HIV/HCV Coinfected People
- ICAAC 2012: New Long-acting HIV Fusion Inhibitor Albuvirtide Looks Promising in Early Studies
- ICAAC 2012: Stribild Quad Pill Has Potent Anti-HIV Activity with Fewer Side Effects
Web Design and Development by